{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:06:18Z","timestamp":1790723178732,"version":"4.1.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    HR-positive HER2-low-expressing breast cancer is a unique subtype that has been refined from the traditional HER2 binary classification system in recent years, accounting for nearly 60% of the overall incidence of breast cancer. It has significant value for precise diagnosis and treatment research. This review systematically elaborates on the epidemiological characteristics, biological basis, diagnostic technology progress, and treatment strategy evolution of this subtype. HR-positive HER2-low-expressing breast cancer is characterized by the dominance of the estrogen receptor pathway and the core molecular feature of the intersection of HER2 low-expression signals. Its diagnosis requires a balance between the fundamental role of endocrine therapy and the precise screening of anti-HER2 targeted therapy. In terms of diagnosis, the initial screening by immunohistochemistry combined with fluorescence\n                    <jats:italic>in situ<\/jats:italic>\n                    hybridization has formed a standardized process. The integration of digital pathology, next-generation sequencing, and circulating tumor DNA in liquid biopsy technologies has effectively improved diagnostic accuracy and dynamic monitoring capabilities. In terms of treatment, endocrine therapy is the cornerstone, and the CDK4\/6 inhibitor combination regimen is the standard for advanced first-line treatment. Antibody-drug conjugates, especially deruxtecan, have significantly improved patient prognosis and reshaped the treatment landscape. In summary, HR-positive HER2-low-expressing breast cancer has entered the era of individualized precise treatment guided by molecular typing. In the future, further exploration of new biomarkers, optimization of combination therapy strategies, and high-quality clinical research are needed to continuously improve patient survival outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1857207","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:23:17Z","timestamp":1784262197000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Yu","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Breast Center, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Breast Center, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Center, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast Center, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Breast Center, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102286","article-title":"Targeting HER2 heterogeneity in breast cancer","volume":"100","author":"Hamilton","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2013.11.011","article-title":"Treatment of HER2-positive breast cancer","volume":"23","author":"Figueroa-Magalhaes","year":"2014","journal-title":"Breast"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0902-sa","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61040644","article-title":"HER2-low breast cancer-current knowledge and future directions","volume":"61","author":"Shaaban","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101615","article-title":"Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer","volume":"8","author":"Viale","year":"2023","journal-title":"ESMO Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/nejmoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchio","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113371","article-title":"Characterisation of luminal and triple-negative breast cancer with HER2 low protein expression","volume":"195","author":"Atallah","year":"2023","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/bctt.s60696","article-title":"PI3K mutations in breast cancer: prognostic and therapeutic implications","volume":"7","author":"Mukohara","year":"2015","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13073-022-01104-z","article-title":"Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas","volume":"14","author":"Berrino","year":"2022","journal-title":"Genome Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-3785","article-title":"Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer","volume":"29","author":"Hensing","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07495-4","article-title":"Genomic and transcriptomic landscape of HER2-low breast cancer","volume":"209","author":"Bansal","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-026-07939-z","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28566","article-title":"GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival","volume":"120","author":"Jiang","year":"2014","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.5319","article-title":"Comparative analysis of human epidermal growth factor receptor 2 testing in breast cancer according to 2007 and 2013 American Society of Clinical Oncology\/College of American Pathologists guideline recommendations","volume":"35","author":"Hanna","year":"2017","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.5858\/arpa.2013-0953-sa","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155472","article-title":"Artificial intelligence for assisted HER2 immunohistochemistry evaluation of breast cancer: A systematic review and meta-analysis","volume":"260","author":"Wu","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.25.6.1551","article-title":"HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies","volume":"25","author":"Tapia","year":"2004","journal-title":"Int J Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2018.2519","article-title":"Standardization and optimization of fluorescence in situ hybridization (FISH) for HER-2 assessment in breast cancer: A single center experience","volume":"18","author":"Bogdanovska-Todorovska","year":"2018","journal-title":"Bosn J Basic Med Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-024-01594-y","article-title":"Exploring the heterogeneity of HER2 gene status and expression in non-positive breast cancer patients: insights from immunohistochemistry and fluorescence in situ hybridization","volume":"20","author":"Zhong","year":"2025","journal-title":"Diagn Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2011.03894.x","article-title":"Dual-color silver-enhanced in-situ hybridization and fluorescence in-situ hybridization for determination of HER2 gene status in gastric carcinoma","volume":"40","author":"Long","year":"2011","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2012.10.003","article-title":"Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma","volume":"15","author":"Wang","year":"2013","journal-title":"J Mol Diagn"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s118502","article-title":"A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation","volume":"9","author":"Frithiof","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqad167","article-title":"HER2\/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer","volume":"161","author":"Xia","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-024-02047-0","article-title":"Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2481825","article-title":"ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+\/HER2-, ESR1-mutated, metastatic breast cancer","volume":"21","author":"Goetz","year":"2025","journal-title":"Future Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz095.015","article-title":"Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer","volume":"49","author":"Guan","year":"2020","journal-title":"Breast"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00456","article-title":"Serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in patients with breast cancer","volume":"8","author":"Shaw","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05662-x","article-title":"Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors","volume":"181","author":"Wang","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102979","article-title":"Advancements in liquid biopsy for breast cancer: Molecular biomarkers and clinical applications","volume":"139","author":"Qiu","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S220726","article-title":"Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with Her2-positive advanced breast cancer in Colombia","volume":"12","author":"Sanchez-Calderon","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2023.09.004","article-title":"Recommendations for cell-free DNA assay validations: A joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"25","author":"Lockwood","year":"2023","journal-title":"J Mol Diagn"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.3171","article-title":"Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials","volume":"34","author":"Regan","year":"2016","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0053","article-title":"NCCN guidelines(R) insights: breast cancer, version 5.2025","volume":"23","author":"Gradishar","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.012","article-title":"Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4","volume":"175","author":"Xu","year":"2022","journal-title":"Eur J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920963925","article-title":"MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase III study","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01564-x","article-title":"ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges","volume":"126","author":"Herzog","year":"2022","journal-title":"Br J Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112689","article-title":"Targeting estrogen receptor alpha for degradation with PROTACs: A promising approach to overcome endocrine resistance","volume":"206","author":"Lin","year":"2020","journal-title":"Eur J Med Chem"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.60.1971","article-title":"Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2","volume":"34","author":"Hortobagyi","year":"2016","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.01.005","article-title":"How I treat HER2-low advanced breast cancer","volume":"67","author":"Schlam","year":"2023","journal-title":"Breast"},{"key":"B52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12577","article-title":"Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I\/Ib study","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06660-x","article-title":"Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer","volume":"194","author":"Vidula","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01245-x","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105852","article-title":"Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib\/II study","volume":"10","author":"Wang","year":"2025","journal-title":"ESMO Open"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101807","article-title":"Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal\/HER2-low breast cancer: PILHLE-001 study","volume":"5","author":"Gong","year":"2024","journal-title":"Cell Rep Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41523-023-00533-2","article-title":"Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer","volume":"9","author":"Pegram","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1101\/2024.07.10.602798","article-title":"NF-\u03baB epigenetic attractor landscape drives breast cancer heterogeneity","volume":"11","author":"Lopes","year":"2025","journal-title":"NPJ Syst Biol Appl"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2025.105818","article-title":"Best pathology practices for HER2 testing interpretation, including HER2-low and ultralow, in the era of HER2-directed antibody drug conjugates (ADCs), aligned with the 2018 CAP\/ASCO HER2 guidelines","volume":"162","author":"Marabi","year":"2025","journal-title":"Hum Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4103\/Singaporemedj.smj-2023-037","article-title":"HER2-low breast cancers: challenges in the interpretation of immunohistochemistry","author":"Chia","year":"2024","journal-title":"Singapore Med J"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1857207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:23:18Z","timestamp":1784262198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1857207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":66,"alternative-id":["10.3389\/fonc.2026.1857207"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1857207","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"1857207"}}